Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma

Journal of Pediatric Surgery

Volumn 41, Issue 8, 2006, Pages 1431-1440

  Azuhata, Takeo ^b   Scott, David ^a   Griffith, Thomas S ^a   Miller, Michal ^a   Sandler, Anthony D ^a  

^a UNIVERSITY OF IOWA   (United States)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Apoptosis; Neuroblastoma; Prognosis; Survivin; TRAIL; Treatment

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; DEATH RECEPTOR 4; DEATH RECEPTOR 5; MESSENGER RNA; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DISSEMINATED CANCER; EVALUATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CHILD; ETOPOSIDE; GANGLIONEUROBLASTOMA; GANGLIONEUROMA; HUMANS; MEMBRANE GLYCOPROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PREDICTIVE VALUE OF TESTS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746076735     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2006.04.020     Document Type: Article

References (39)

1. Brodeur G.M., and Castleberry R.P. Neuroblastoma. In: Pizzo P.A., and Poplack D.G. (Eds). Principles and practice of pediatric oncology. 3rd ed (1997), JB Lippincott, Philadelphia 761-797
2. Steller H. Mechanisms and genes of cellular suicide. Science 267 (1995) 1445-1449
3. Armitage R.J. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 6 (1994) 407-413
4. Cosman D. A family of ligands for the TNF receptor superfamily. Stem Cells 12 (1994) 440-455
5. Griffith T.S., Brunner T., Fletcher S.M., et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995) 1189-1992
6. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
7. Pitti R.M., Marsters S.A., Ruppert S., et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271 (1996) 12687-12690
8. Griffith T.S., Chin W.A., Jackson G.C., et al. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161 (1998) 2833-2840
9. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of TRAIL in vivo. Nat Med 5 (1999) 157-163
10. Ashkenazi A., Pai R.C., Fong S., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
11. Gliniak B., and Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59 (1999) 6153-6158
12. Ambrosini G., Adid A., and Altieri D. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
13. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
14. Li F., Ackermann E.J., Bennett C.F., et al. Pleiotropic cell division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1 (1999) 461-466
15. Sandler A.D., Okamoto S., Wen J., et al. Survivin in apoptosis and solid tumors of childhood. Surg Forum 50 (1999) 571-572
16. Azuhata T., Scott D.L., Takamizawa S., et al. The inhibitor of apoptosis protein survivin is associated with high risk behavior of neuroblastoma. J Pediatr Surg 36 12 (2001) 1785-1791
17. Adida C., Berrebi D., Peuchmaur M., et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351 (1998) 882-883
18. Griffith T.S., Rauch C.T., Smolak P.J., et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 162 (1999) 2597-2605
19. Shapiro D.N., Valentine M.B., Rowe S.T., et al. The survivin:Fas ratio in pediatric renal tumors. Am J Pathol 142 (1993) 1339-1346
20. Flick D.A., and Gifford G.E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 68 (1984) 167-175
21. Martin S.J., Reutelingsperger C.P.M., McGahon A.J., et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182 (1995) 1545-1556
22. Pan G., O'Rourke K., Chinnaiyan A.M., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
23. Walczak H., Degli-Esposti M.A., Johnson R.S., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16 (1997) 5386-5397
24. Pan G., Ni J., Wei Y.-F., et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
25. Sheridan J.P., Marsters S.A., Pitti P.M., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
26. Degli-Esposti M.A., Dougall W.C., Smolak P.J., et al. The novel receptor TRAIL-R4 induces NFκB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 (1997) 813-820
27. Marsters S.A., Sheridan J.P., Pitti R.M., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7 (1997) 1003-1006
28. Enari M., Hug H., and Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375 (1995) 78-81
29. Hawkins C.J., and Vaux D.L. The role of the Bcl-2 family of apoptosis regulatory proteins in the immune system. Semin Immunol 9 (1997) 25-33
30. Tschopp J., Irmler M., and Thome M. Inhibition of Fas death signals by FLIPs. Curr Opin Immunol 10 (1998) 552-558
31. Zhang X.D., Franco A.V., Nguyen T., et al. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 164 (2000) 3961-3970
32. LeBlanc H., Lawrence D., Varfolomeev E., et al. Tumor cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8 3 (2002) 274-281
33. Hacker G., Hawkins C.J., et al. Effects of viral inhibitors of apoptosis in models of mammalian cell death. Behring Inst Mitt 97 (1996) 118-126
34. Irmler M., Thome M., Hahne M., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
35. Leverkus M., Neumann M., Mengling T., et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60 (2000) 553-559
36. Takamizawa S., Scott D., Wen J., et al. The survivin:Fas ratio in pediatric renal tumors. J Pediatr Surg 36 1 (2001) 37-42
37. Lu C.-D., Altieri D.C., and Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58 (1998) 1808-1812
38. cdc2. Proc Natl Acad Sci U S A 97 (2000) 13103-13107
39. Sandler A.D., Scott D., Azuhata T., et al. The survivin:Fas ratio is predictive of recurrent disease in Neuroblastoma. J Pediatr Surg 37 (2002) 507-511